GLP-1 Dosing Charts: Key Brand Variations

Last reviewed: June 6, 2026

Last updated: June 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

GLP-1 receptor agonists like semaglutide and tirzepatide are prescribed using structured dosing schedules designed to minimize side effects while maximizing metabolic benefit. Each formulation—whether injectable, oral, or compounded—follows its own titration pathway, and individual factors including genetics, metabolic history, and gastrointestinal tolerance can influence how quickly a patient advances through dose levels.

How Injectable Semaglutide Dosing Works

Injectable semaglutide follows a four-week titration cycle starting at 0.25 mg weekly, then increasing to 0.5 mg, 1 mg, and potentially 2 mg over successive weeks. This gradual step-up approach allows your body to adapt to the medication while your provider monitors efficacy and tolerability. Most patients experience meaningful appetite suppression and weight loss within the first four weeks, though response varies based on metabolic factors and adherence.

PlexusDx compounded semaglutide injections are prepared in licensed 503A pharmacies to match these clinical protocols, at $189/mo month-to-month, or from $149/mo on the 6-month plan regardless of dose level. Your dose may need to go up over time—your price won't. The flat monthly rate removes cost barriers to dose optimization, allowing your provider to titrate based on clinical response rather than financial constraints.

Tirzepatide Injection Schedules and Progression

Tirzepatide, a dual GIP/GLP-1 receptor agonist, uses a four-week titration beginning at 2.5 mg weekly, advancing through 5 mg, 7.5 mg, 10 mg, and up to 15 mg based on individual response. Because tirzepatide targets two distinct peptide pathways rather than one, many patients report stronger appetite reduction and faster metabolic improvements compared to semaglutide alone. Clinical trials show tirzepatide-treated patients achieve 20–22% weight loss at the highest approved doses, compared to 15–18% with semaglutide.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR (rs1800437) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Oral Formulation Dosing Differences

Oral semaglutide and oral tirzepatide follow different dosing rhythms than injectable versions because they must overcome gastrointestinal absorption challenges. Oral semaglutide tablets start at 3 mg daily, titrating upward to 7 mg and 14 mg, while oral tirzepatide begins at 2.5 mg daily and progresses to 5 mg, 10 mg, and 15 mg. Both require specific administration protocols—taking tablets on an empty stomach with limited water—to maximize bioavailability.

Oral formulations appeal to patients who prefer needle-free therapy, though weekly injections typically deliver more consistent drug exposure. PlexusDx oral semaglutide is $289/mo month-to-month (or $249/mo on the 6-month plan) and oral tirzepatide at $349/mo (or $279/mo on the 6-month plan), each with flat-rate pricing across all dose levels. Absorption differences mean some patients require higher oral doses to achieve results equivalent to lower injectable doses.

Compounded vs. Brand-Name Dosing Protocols

Brand-name semaglutide (Ozempic for diabetes, Wegovy for weight loss) and tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) follow FDA-established dosing schedules, but compounded versions from licensed 503A pharmacies maintain identical titration protocols and pharmacological action. The key difference is cost and accessibility: compounded medications eliminate branded markups and distribution fees, making progressive dose optimization financially sustainable for patients without insurance coverage.

PlexusDx compounds all GLP-1 medications through verified 503A pharmacies—never 503B facilities—ensuring pharmaceutical-grade preparation and quality control. Dosing decisions depend on clinical response, not price tier, because PlexusDx uses flat monthly rates. A patient whose provider recommends advancing from 0.5 mg to 1 mg semaglutide pays the same $189 monthly fee, enabling evidence-based prescribing free from cost-based barriers.

Personalized Dosing With Genetic Testing

The PlexusDx Precision Peptide Genetic Test analyzes GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to GLP-1 medications or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

The PlexusDx Precision Peptide Genetic Test ($298) maps 14 distinct peptide pathways, analyzes 49 individual peptides, and delivers 150+ genetic insights specific to your GLP-1 response profile. This personalized roadmap allows your provider to anticipate dosing needs, select between semaglutide, tirzepatide, or dual-compound therapy (GLP-Squared), and adjust titration speed based on your unique genetic architecture rather than one-size-fits-all protocols.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What is the standard starting dose for semaglutide injection?

Injectable semaglutide treatment begins at 0.25 mg weekly, then increases by 0.25 mg every four weeks up to a therapeutic dose of 1–2 mg weekly. PlexusDx compounded semaglutide is $189 monthly month-to-month, or from $149/mo on the 6-month plan regardless of which dose level your provider prescribes, ensuring you're never charged more as your dose advances.

How does tirzepatide dosing differ from semaglutide?

Tirzepatide starts at 2.5 mg weekly and escalates through 5 mg, 7.5 mg, 10 mg, and 15 mg, following a similar four-week cycle as semaglutide. Because tirzepatide activates both GIP and GLP-1 pathways, many patients advance faster and achieve greater weight loss at equivalent timepoints. Clinical trials show tirzepatide delivers 20–22% weight loss versus 15–18% for semaglutide at maximum approved doses.

Does PlexusDx charge different prices for different dose levels?

No. PlexusDx uses flat monthly pricing—semaglutide injections are $189/mo month-to-month, or from $149/mo on the 6-month plan, tirzepatide injections at $289/mo (or $249/mo on the 6-month plan)—regardless of dose escalation. Your dose may need to go up over time, but your price won't, eliminating financial barriers to dose optimization based on clinical response.

Can oral semaglutide achieve the same results as injections?

Oral semaglutide can produce weight loss and metabolic benefits, but typically requires higher doses (up to 14 mg daily) to match the efficacy of 1–2 mg weekly injections due to lower bioavailability. Oral formulations appeal to needle-averse patients and are available through PlexusDx at $289 monthly, though injectable therapy generally delivers faster, more predictable results.

How does the PlexusDx Precision Peptide Genetic Test personalize dosing?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Best Brand Name Glp 1 Telehealth Providers Plexusdx
• How Do Genetic Variations Impact Glp 1 Response
• Maximus Glp 1
• Found Glp 1

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.